skip to Main Content

GI Armamentarium Undergoes Changes With New Treatment Mechanisms and Applications

Newsfeed image, light gray text on dark gray background
The investigation of new drugs with novel mechanisms of action such as surufatinib and PEN-221 in neuroendocrine tumors (NETs), the use of DNA-damaging agents like olaparib (Lynparza) in pancreatic cancer, and the applications of surgery and systemic therapy in settings that challenge historical dogmas are some of the exciting takeaways from an Institutional Perspectives in Cancer webinar on gastrointestinal malignancies, explained Chih-Yi (Andy) Liao, MD.


“For pancreatic cancer, there are a lot of new, exciting targets and treatment options that are being developed. I highly encourage patients to consider clinical trials that are looking at these new treatment strategies. For NETs as well, we’re looking at other new systemic therapies that might be beneficial,” Liao, chair of the event and an assistant professor of medicine at the University of Chicago, said in an interview with OncLive®. Read more . . . 

Back To Top